Abstract:The Canadian Journal of Psychiatry, Ahead of Print. ObjectivesThe majority of patients with schizophrenia experience dramatic improvement in psychotic symptoms when treated with antipsychotic medication. Maintenance treatment can prevent relapses but problems with medication adherence limit effectiveness. Long-acting injectable antipsychotics (LAIs) provide an opportunity to establish adherence but challenges remain in ensuring that the dose selected is therapeutic. Therapeutic drug monitoring has not been established as valuable for LAIs in the maintenance treatment of schizophrenia. This exploratory study was undertaken to describe plasma paliperidone levels in outpatients treated with the LAI paliperidone palmitate and to determine whether paliperidone levels are associated with subjective experience on medication and side effects.MethodsTwenty-one outpatients with schizophrenia receiving treatment with LAI paliperidone consented to participation in this study. Blood samples were obtained for measurement of paliperidone and prolactin levels at the first visit. A second paliperidone level was obtained at the time of the next injection for 18 of the participants. Clinical rating scales were administered at the first visit to assess illness severity, attitudes regarding medication, subjective well-being and side effects.ResultsPaliperidone levels were highly correlated at the two time points (ρ = .85; P < .001). Mean paliperidone level at the first visit was 34.9 ng/ml and ranged from 5.1 to 73.9 ng/ml. Higher paliperidone levels were correlated with higher prolactin levels (ρ = 0.59, P < .01) and lower sexual desire (ρ = −.58, P < .01).ConclusionsWe demonstrated that paliperidone levels can be measured reliably in patients receiving LAI paliperidone. Higher plasma levels were associated with higher prolactin levels and reduced sexual desire but not with measures of subjective experience on medications or other side effects. Measurement of paliperidone levels in patients treated with paliperidone palmitate may have the potential to minimize the dose of medication prescribed and, in turn, the severity of sexual side effects.Plain Language Summary TitleCan the Dosing of Long-Acting Injectable Paliperidone for the Treatment of Schizophrenia Be Improved by Measuring Drug Levels?Plain Language SummaryWhy was the study done?Antipsychotic medications are able to make the hallucinations and delusional thoughts go away for most people who have schizophrenia. Providing the medication in the form of an injection that can be given every few weeks or months can help people with schizophrenia stay well. It can be hard to know what dose of the injectable antipsychotic paliperidone will be best for each person. If the dose is too low, symptoms will return. If the dose is too high, side effects can be difficult to tolerate. This exploratory study was done to see whether measuring the amount of paliperidone in the blood can be used to make sure that the dose is likely to be effective and well tolerated.What did the researchers do?People with schizophrenia who were being treated with the long-acting injectable paliperidone had their blood drawn to measure the level of medication just before they received their next injection. Researchers also measured the symptoms and side effects that participants were experiencing to see whether people who had higher levels of paliperidone in their blood had more side effects.What did the researcher find?Even at the same dose of medication, some people had very small amounts of medication in their blood and others had much higher amounts. People with higher amounts in their blood experienced less sexual desire.What do the findings mean?The amount of paliperidone in the blood is a better measure of how much medication a person is getting than the dose they are given. Measuring paliperidone blood levels may lead to lower doses with fewer sexual side effects. It may make it easier for people with schizophrenia to continue on medication and to stay well.

Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models

An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics

Microcrystals of Ketal-Linked Paliperidone Prodrugs for Long-Acting Antipsychotics

Injectable, porous, biohybrid hydrogels incorporating decellularized tissue components for soft tissue applications.

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers

Long-Acting Paliperidone Parenteral Formulations Based on Polycaprolactone Nanoparticles; the Influence of Stabilizer and Chitosan on In Vitro Release, Protein Adsorption, and Cytotoxicity

Hyaluronidase Inhibitor-Incorporated Cross-Linked Hyaluronic Acid Hydrogels for Subcutaneous Injection

Hydrogel formats to model potential drug interactions occurring at the subcutaneous injection site

Halting hyaluronidase activity with hyaluronan-based nanohydrogels: development of versatile injectable formulations

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer

Validation of the Absorption-Enhancing Ability of Oligoarginines Grafted onto a Backbone of Hyaluronic Acid through Animal Studies from Rodents to Primates

An injectable hydrogel based on hyaluronic acid prepared by Schiff base for long-term controlled drug release

Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Evaluating the Impact of Human Factors and Pen Needle Design on Insulin Pen Injection

Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corrélats cliniques des concentrations plasmiques de palipéridone à libération prolongée

Albumin affibody-outfitted injectable gel enabling extended release of urate oxidase-albumin conjugates for hyperuricemia treatment

pH-Responsive and Mucoadhesive Nanoparticles for Enhanced Oral Insulin Delivery: The Effect of Hyaluronic Acid with Different Molecular Weights

Observation of Clinically Relevant Drug Interaction in Chimeric Mice with Humanized Livers: The Case of Valproic Acid and Carbapenem Antibiotics

Comparison of Intra-arterial and Subcutaneous Testicular Hyaluronidase Injection Treatments and the Vascular Complications of Hyaluronic Acid Filler.

Kinetic and Mechanistic Release Studies on Hyaluronan Hydrogels for Their Potential Use as a pH-Responsive Drug Delivery Device

Unraveling enhanced brain delivery of paliperidone-loaded lipid nanoconstructs: pharmacokinetic, behavioral, biochemical, and histological aspects